Business Wire

JDI

23.8.2024 09:01:29 CEST | Business Wire | Press release

Share
JDI Develops World's First Automotive Grade Dual Touch 2 Vision Display (2VD)

This press release is intended to redistribute the content that was already disclosed on August 2, 2024, for an international audience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823676155/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2 Vision Display (Graphic: Business Wire)

JDI has developed the world's first 2 Vision Display (2VD) technology that meets automotive grade image quality requirements while simultaneously displaying different image content based on viewing direction. As another world's first, JDI has incorporated Dual Touch into its new 2VD technology that identifies discrete touch operations from different users. JDI Dual Touch 2VD thus enables a single display to function as two separate touch-enabled displays.

2VD has existed as a concept for many years. Unfortunately, it has historically been unable to overcome image quality issues to achieve commercialization and product use.

With its new Dual Touch 2VD technology, JDI has deployed its world-leading LTPS and optics capabilities to generate the necessary breakthrough in image quality to allow for widespread use. As an automotive use case, JDI Dual Touch 2VD simultaneously provides a large-screen, rich-content information display to the driver to support safe driving and a large-screen, high-quality passenger display on a single display. Dual Touch 2VD also resolves interior design constraints caused by the increase in displays, while allowing the reduction of in-car display usage to support streamlined and sophisticated interior designs.

2VD has also historically lacked touch functionality, an important capability for many use cases. JDI Dual Touch 2VD uses JDI-developed custom ICs to identify whether touch operations originate from the driver or passenger (again, using an automotive use case example), allowing a single display to function as two separate touch-enabled displays.

JDI is currently in discussions with multiple global automobile OEMs to incorporate JDI Dual Touch 2VD into their next-generation vehicle interiors, with first shipment possible as early as 2025. In collaboration with these OEMs, JDI is working to create unprecedented levels of automobile safety and comfort.

Existing 2VD vs. New JDI Dual Touch 2VD

 

 Existing 2VD

New JDI

Dual Touch 2VD

Resolution

88 ppi

171 ppi

Brightness

350 nits

700 nits

Contrast

350 : 1

1000 : 1

NTSC Ratio

70%

85%

Touch Functionality

None

Dual Touch

Furthermore, JDI Dual Touch 2VD’s rich functionality goes beyond the automotive industry. It has a broad set of use cases in an extraordinarily rich variety of contexts, locations, and industries and in both horizontal and vertical 2VD modes. As examples, JDI Dual Touch 2VD can be deployed in large signage applications or to create display security and privacy enhancements through viewing angle control, or to support innovative gaming applications.

A sample vertical use case of JDI Dual Touch 2VD would be a large display at a transportation hub such as an airport or train station, in which the changing user viewing angle, depending on the distance between the display and the user, allows for the simultaneous provision of rich visuals, art or other creative content, general information, or advertising (at a distance) and departure/arrival information (up close).

JDI Dual Touch 2VD is a breakthrough display technology that has the potential to change the way displays are used – and shared – all over the world in fundamentally new ways. JDI looks forward to open innovation and collaboration with individuals, organizations, and creative communities globally to explore new use cases for JDI Dual Touch 2VD that enrich people’s daily lives. Please feel free to contact us at:
https://www.webcoms.jp/jdi/eng/form.php?pid=524

2 Vision Display presentation video
https://youtu.be/zBnz1GirUYE

[Provisional Translation Only]
This translation is provided solely for information purposes.
Should there be any discrepancies between this translation and the Japanese original, the latter shall prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240823676155/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release

Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release

Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be

From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release

Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and

Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 14:30:00 CEST | Press release

Public equities have re-emerged as the primary destination for incremental capital Private markets remain a strategic pillar of family office portfolios Artificial intelligence is moving from experimentation toward implementation Cross-border complexity is rising as families become increasingly international Leadership succession and next-generation preparedness are now immediate priorities rather than distant considerations Watch Citi Wealth’s Global Family Office leadership discuss the report’s findings here. Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Tod

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 14:30:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye